Overview

Evaluation of the Absolute Bioavailability and Mass Balance of CHF6001 (Tanimilast)

Status:
Completed
Trial end date:
2021-04-29
Target enrollment:
Participant gender:
Summary
The objective of the proposed study is to evaluate the bioavailability of CHF6001 after inhaled administration and to characterize the mass balance and route of elimination of CHF6001 in human along with its relevant metabolites.
Phase:
Phase 1
Details
Lead Sponsor:
Chiesi Farmaceutici S.p.A.